As­traZeneca spin­out Viela Bio pock­ets $75M on its way to BLA for au­toim­mune drug

On the verge of a BLA fil­ing for its lead drug in a pipeline spun out of As­traZeneca, Viela Bio has pushed its ven­ture fund­ing over the $300 mil­lion line.

The $75 mil­lion Se­ries B comes over a year af­ter the phar­ma gi­ant’s Med­Im­mune sub­sidiary pack­aged six drugs from its res­pi­ra­to­ry, in­flam­ma­tion & au­toim­mune unit in­to a $250 mil­lion biotech play­er. Bing Yao, who head­ed that team, is lead­ing Viela Bio as CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER